Skip to main content
Fig. 5 | BMC Cardiovascular Disorders

Fig. 5

From: Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study

Fig. 5

Changes in pulmonary artery systolic pressure (PASP, estimated by tricuspid regurgitation velocity, a) and in pulmonary capillary wedge pressure (PCWP, estimated by mitral E/e′ ratio, b) during cycle exercise at baseline and after 6 months. Ex., exercise. * P < 0.05 vs baseline

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us